LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 8%

LAVA Therapeutics (NASDAQ:LVTX)’s share price traded up 8% during mid-day trading on Monday . The stock traded as high as $2.53 and last traded at $2.44. 76,769 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 1,111,030 shares. The stock had previously closed at $2.26.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of LAVA Therapeutics in a report on Thursday, March 21st.

LAVA Therapeutics Stock Down 0.9 %

The firm has a market capitalization of $58.56 million, a PE ratio of -2.14 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.42 and a quick ratio of 7.42. The company has a 50-day moving average price of $2.84 and a 200 day moving average price of $2.27.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.40). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $25.00 million. LAVA Therapeutics had a negative return on equity of 51.90% and a negative net margin of 228.02%. Analysts forecast that LAVA Therapeutics will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC bought a new stake in shares of LAVA Therapeutics (NASDAQ:LVTX) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $47,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.